HC Wainwright restated their buy rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a research note released on Monday. They currently have a $62.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on XLRN. Royal Bank of Canada assumed coverage on shares of Acceleron Pharma in a report on Thursday, September 14th. They issued a sector perform rating and a $44.00 price target on the stock. Oppenheimer reissued a hold rating on shares of Acceleron Pharma in a report on Wednesday, September 20th. Cann reissued a hold rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. ValuEngine downgraded shares of Acceleron Pharma from a hold rating to a sell rating in a report on Friday, October 6th. Finally, UBS reissued a buy rating and issued a $50.00 price target (up from $36.00) on shares of Acceleron Pharma in a report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $44.56.

Acceleron Pharma (XLRN) opened at $37.65 on Monday. Acceleron Pharma has a fifty-two week low of $23.07 and a fifty-two week high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.55) EPS. equities analysts anticipate that Acceleron Pharma will post -2.65 earnings per share for the current fiscal year.

In related news, major shareholder Corp /De/ Celgene purchased 745,592 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were purchased at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the completion of the transaction, the insider now directly owns 6,118,479 shares in the company, valued at approximately $226,383,723. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.90% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in XLRN. Quantbot Technologies LP increased its position in shares of Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,352 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Acceleron Pharma by 969.9% during the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 3,288 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of Acceleron Pharma during the third quarter valued at about $225,000. PNC Financial Services Group Inc. increased its position in shares of Acceleron Pharma by 57.8% during the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 3,100 shares during the period. Finally, Trexquant Investment LP bought a new stake in shares of Acceleron Pharma during the third quarter valued at about $266,000. Hedge funds and other institutional investors own 85.84% of the company’s stock.

WARNING: “HC Wainwright Reaffirms Buy Rating for Acceleron Pharma (XLRN)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-acceleron-pharma-xlrn/1762526.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.